

company announcement

Novo Nordisk A/S – Share repurchase programme

Bagsværd, Denmark, 1 April 2015 – On 30 January 2015, Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules. This programme is part of the overall share repurchase programme of up to DKK 15.0 billion to be executed during a 12-month period beginning 30 January 2015.

Under the programme initiated 30 January 2015, Novo Nordisk will repurchase B shares for an amount up to DKK 3.7 billion in the period from 30 January 2015 to 28 April 2015.

Since the announcement as of 23 March 2015, the following transactions have been made under the programme:

	Number of B shares	Average purchase price	Transaction value, DKK
Accumulated, last announcement	7,219,481		2,214,224,053
23 March 2015	185,000	338.44	62,612,103
24 March 2015	170,000	343.87	58,458,291
25 March 2015	190,000	341.88	64,957,656
26 March 2015	210,000	334.94	70,336,371
27 March 2015	165,000	370.82	61,184,475
30 March 2015	150,000	372.99	55,949,070
31 March 2015	180,000	373.27	67,189,230
Accumulated under the programme	8,469,481		2,654,911,249

With the transactions stated above, Novo Nordisk owns a total of 67,108,333 B shares of DKK 0.20, corresponding to 2.5% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,650,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 15.0 billion during a 12-month period beginning 30 January 2015. As of 31 March 2015, Novo Nordisk has repurchased a total of 8,469,481 B shares equal to a transaction value of DKK 2,654,911,249.

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 41,500 employees in 75 countries, and markets its products in more than 180 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, [Facebook](#), [Twitter](#), [LinkedIn](#), [YouTube](#)

Further information

Media:

Anne Margrethe Hauge +45 3079 3450 amhg@novonordisk.com

Investors:

Kasper Roseeuw Poulsen +45 3079 4303 krop@novonordisk.com

Daniel Bohsen +45 3079 6376 dabo@novonordisk.com

Melanie Raouzeos +45 3075 3479 mrz@novonordisk.com

Frank Daniel Mersebach (US) +1 609 235 8567 fdni@novonordisk.com